首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   862799篇
  免费   71667篇
  国内免费   1840篇
耳鼻咽喉   12806篇
儿科学   24673篇
妇产科学   25142篇
基础医学   124474篇
口腔科学   25503篇
临床医学   75536篇
内科学   164856篇
皮肤病学   16992篇
神经病学   70408篇
特种医学   35284篇
外国民族医学   171篇
外科学   136352篇
综合类   24614篇
现状与发展   2篇
一般理论   264篇
预防医学   66998篇
眼科学   20571篇
药学   64754篇
中国医学   1593篇
肿瘤学   45313篇
  2018年   7382篇
  2015年   7752篇
  2014年   11165篇
  2013年   16874篇
  2012年   22822篇
  2011年   23934篇
  2010年   13916篇
  2009年   13118篇
  2008年   22687篇
  2007年   24733篇
  2006年   24614篇
  2005年   24247篇
  2004年   23793篇
  2003年   22926篇
  2002年   21999篇
  2001年   35889篇
  2000年   36533篇
  1999年   30958篇
  1998年   9241篇
  1997年   8568篇
  1996年   8493篇
  1995年   8025篇
  1994年   7740篇
  1992年   26698篇
  1991年   26136篇
  1990年   25651篇
  1989年   24709篇
  1988年   23263篇
  1987年   22919篇
  1986年   21776篇
  1985年   21117篇
  1984年   16410篇
  1983年   14015篇
  1982年   8865篇
  1981年   8208篇
  1980年   7678篇
  1979年   16751篇
  1978年   12125篇
  1977年   10190篇
  1976年   9335篇
  1975年   10165篇
  1974年   12647篇
  1973年   12147篇
  1972年   11547篇
  1971年   10699篇
  1970年   10227篇
  1969年   9918篇
  1968年   8910篇
  1967年   8236篇
  1966年   7657篇
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
51.
52.
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment.  相似文献   
53.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance.  相似文献   
54.
55.
56.
57.
58.
59.
60.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号